mardi 4 octobre 2016

Onco Actu du 4 octobre 2016

1. Biologie

Nobel Prize 2016: What Ohsumi’s discovery of cellular ‘self-eating’ means for cancer [Cancer Research UK]

Yoshinori Ohsumi of Japan Wins Nobel Prize in Medicine [NY Times]

5.2 Pharma

US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC [Roche]

Samsung Bioepis seeks Europe approval for copy of Herceptin breast cancer drug [Reuters]

Roche say cancer drug Alecensa gets breakthrough therapy designation [Reuters]

5.2.3 Pharma - économie

Still Stuck Below IPO Price, Merrimack Restructures, CEO Resigns [Xconomy]

5.4 Traitements - Economie

Panel releases best practices in cost-effectiveness analysis [PhRMA]

NICE recommends new drug osimertinib for hundreds of people with lung cancer [NICE]

ICER on PD-1 Immunotherapies to Treat Lung Cancer: Lower the Prices [RAPS]

'Breakthrough' lung cancer drug made available on NHS [The Guardian]

5.6 ESMO

New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach [BMS]

6.10.1 Politiques (USA)

US Zika funding shortfall will impede cancer research, health officials say [The Guardian]

6.11 Patients

When noncompliance is your best option [Outliving Lung Cancer]

Dying woman picks road trip over chemotherapy [BBC News]

6.3 Associations/Fondations

Crowdsourcing effort takes aim at deadliest breast cancers [STAT]

6.7 DMP, Big Data & applis

Democratic databases: science on GitHub [Nature]

precisionFDA’s Next Challenge? Conduct an App-a-Thon! [FDA Voice]